Athna Biotech Inc.
Watkinsville, GA
- UEI
- LBCCTS71U2N4
- CAGE
- 8CKB5
- Primary NAICS
- 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- SAM.gov registration
- Active through
Company facts
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- Other NAICS codes in SAM.gov
- SAM.gov registration date
- Physical address
- 1070 Crabapple Cir, Watkinsville, GA 30677, USA
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Grant awards
Similar vendors
| Vendor | Location | Primary NAICS |
|---|---|---|
| Senex Biotechnology Inc. | Maynard, MA | 541714 Research and Development in Biotechnology (except Nanobiotechnology) |
| Viewpoint Molecular Targeting, Inc. | Coralville, IA | 541714 Research and Development in Biotechnology (except Nanobiotechnology) |
| PDX Pharmaceuticals Inc. | Portland, OR | 541713 Research and Development in Nanotechnology |
| Nanocan Therapeutics Corporation | Forest Heights, MD | 541713 Research and Development in Nanotechnology |
| Creative Biotherapeutics LLC | Gurnee, IL | — |
About the company
Athna Biotech Inc. is a for-profit corporate entity registered in SAM.gov since June 19, 2019, located in Watkinsville, Georgia. The company appears to be a biotechnology research firm focused on developing innovative nanomedicine solutions for cancer treatment, with a specific emphasis on targeted therapeutic approaches for various cancer types. While limited information is available about the company's full operational scope, its federal grant award history suggests a strong research orientation in advanced cancer treatment technologies.
The company has received multiple federal grant awards from the National Cancer Institute, focusing on developing specialized nanoparticle-based cancer therapies. Specifically, Athna Biotech has pursued two primary research projects: a sodium chloride nanoparticle (SCNP) therapeutic for non-muscle invasive bladder cancer and a radiation-activatable nanoparticle approach for lung cancer therapy. The bladder cancer project involves developing a novel intravesical treatment that induces immunogenic cell death, while the lung cancer project centers on creating a radiation-responsive prodrug delivery system using targeted nanoparticles. These grants, awarded in 2021 and 2022, demonstrate the company's innovative approach to cancer treatment, with research periods extending through 2024 and 2027. The projects involve sophisticated medical research strategies, including nanoparticle design, targeted drug delivery, and methods to enhance radiation therapy effectiveness while minimizing systemic toxicity.
Quick answers
Is Athna Biotech Inc. registered in SAM.gov?
Yes. Athna Biotech Inc.'s SAM.gov registration is active through January 6, 2027.
What is Athna Biotech Inc.'s most recent federal award?
Athna Biotech Inc.'s most recent federal grant award is Development of a salt-based nanomedicine for non-muscle invasive bladder cancer (R43CA262399), from National Cancer Institute (NIH), on May 5, 2022.
On GovTribe
See Athna Biotech Inc.'s full federal record
- Federal grant awards
- Funding analysis by agency, NAICS and set-aside
- Similar vendors